Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
무작위 임상시험
4/5 보강
TL;DR
It is concluded that finasteride causes profound decrease in prostatic dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.
📑 코퍼스 인용 관계
· 인용됨 8
📑 인용한 논문 (6) ▾
- Dihydrotestosterone and Finasteride Effects on Alcohol Cue-Elicited Brain Activity in Male… Addiction biology · 2026
- Differential association between cumulative dose of 5α-reductase inhibitors and mortality. Scientific reports · 2025
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses… Cureus · 2021
- Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche … Journal of biomedical science · 2020
- Development of finasteride polymer microspheres for systemic application in androgenic alo… International journal of molecular medicine · 2019
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the t… Therapeutic advances in urology · 2016
연도별 인용 (2012–2025) · 합계 83
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Hormonal and reproductive studies
Sexual Differentiation and Disorders
Abstract 🌐 Abstract
The oral administration of finasteride, a 4-aza-steroid inhibitor of 5 alpha-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 +/- 0.6 nmol/kg (+/- SE), and the mean concentration of testosterone was 0.7 +/- 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.
It is concluded that finasteride causes profound decrease in prostatic dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia.
APA 7
McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Pappas, F., & Stoner, E. (1992). Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.. The Journal of clinical endocrinology and metabolism, 74(3), 505-8. https://doi.org/10.1210/jcem.74.3.1371291
Vancouver
McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Jour. clin. endo. meta.. 1992;74(3):505-8. doi:10.1210/jcem.74.3.1371291
AMA 11
McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Jour. clin. endo. meta.. 1992;74(3):505-8. doi:10.1210/jcem.74.3.1371291
Chicago
McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Pappas, F., and Stoner, E.. 1992. "Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia." The Journal of clinical endocrinology and metabolism 74 (3): 505-8. https://doi.org/10.1210/jcem.74.3.1371291
MLA 9
McConnell, J. D., et al. "Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia." The Journal of clinical endocrinology and metabolism, vol. 74, no. 3, 1992, pp. 505-8. doi:10.1210/jcem.74.3.1371291.
PMID
1371291 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 8/8 (100%)
· 참조 0편 · 후속 8편
이 논문을 인용한 후속 연구 8
- Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunctio…
- Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time…
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
- Differential association between cumulative dose of 5α-reductase inhibitors and mortality.
- Dihydrotestosterone and Finasteride Effects on Alcohol Cue-Elicited Brain Activity in Males With Hea…
- Should Finasteride Be Routinely Given Preoperatively for TURP?
같은 제1저자의 인용 많은 논문 (5)
- The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
- The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
- Benign prostatic hyperplasia. Hormonal treatment.
- BPH: what really works?
- Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.